ArticleScientific reports2026
Development of surfactin-based nanocarrier for targeted doxorubicin delivery.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Surfactin, one of the most powerful lipopeptide biosurfactants produced by Bacillus subtilis, has great potential for biomedical applications. Isolation, purification, and characterization of surfactin from Bacillus subtilis 6633 to be used as a doxorubicin (Dox) nanocarrier. Purified surfactin using different chromatographic columns was used to prepare a self-assembled nanocarrier for Dox, which was characterized for size, charge, and drug-loading efficiency. Biological activity against normal fibroblast (FB) and liver cancer (HepG2) cells was assessed. The hybrid nanoparticles showed a remarkable drug loading; 36%, a pH-responsive release profile with enhanced cytotoxicity toward HepG2 cells (IC₅₀ = 5.40 µg/mL), and a reduced toxicity to FB cells (IC₅₀ = 12.78 µg/mL). The nanoparticles were spherical in shape (100 ± 2 nm) with a polydisperse index of (0.019 ± 0.01) and a narrow size distribution pattern. The results support the potential of surfactin-based nanoparticles to act as a selective platform for anticancer drug delivery and underscore their relevance towards the Sustainable Development Goal 3 (Good Health and Well-being) through the development of safer and effective therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.